Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Leukemia, Myeloid, Acute 54Multiple Myeloma 45Lymphoma 44Lymphoma, Non-Hodgkin 41Leukemia 38Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Hodgkin Disease 35Myelodysplastic Syndromes 34Lymphoma, Mantle-Cell 20Lymphoma, Large B-Cell, Diffuse 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19Leukemia, Lymphocytic, Chronic, B-Cell 16Burkitt Lymphoma 16Breast Neoplasms 13Neoplasms, Plasma Cell 11Recurrence 10Lymphoma, Follicular 10Hematologic Neoplasms 9Anemia, Refractory, with Excess of Blasts 9Lymphoma, B-Cell, Marginal Zone 8Neuroblastoma 7Myeloproliferative Disorders 7Lymphoma, Large-Cell, Immunoblastic 7Central Nervous System Neoplasms 7Blast Crisis 7Neoplasms 6Lymphoma, T-Cell 6Leukemia, Myelomonocytic, Juvenile 6Leukemia, Myelomonocytic, Chronic 6Graft vs Host Disease 6

Interventions

Rituximab 8Cyclophosphamide 8Peripheral Blood Stem Cell Transplantation 7Methotrexate 7fludarabine phosphate 6Whole-Body Irradiation 5Tacrolimus 5Mycophenolic Acid 5Dexamethasone 5Cyclosporine 5Cytarabine 4Transplantation 3Radiotherapy 3Filgrastim 3Busulfan 3pegfilgrastim 2merphos 2etoposide phosphate 2Methylprednisolone 2Lenalidomide 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Carboplatin 2Calcium Dobesilate 2Antilymphocyte Serum 2zanubrutinib 1sodium thiosulfate 1sargramostim 1oblimersen 1ibrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Intraocular Lymphoma × Granulocyte Colony-Stimulating Factor × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

NCT01110135 2017-05-24

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

University of Washington

Phase 2 Completed
43 enrolled 5 charts
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡